| (Values in U.S. Thousands) | Mar, 2026 | Dec, 2025 | Sep, 2025 | Jun, 2025 | Mar, 2025 |
| Sales | 3,740 | 1,280 | 1,080 | 1,350 | 2,740 |
| Sales Growth | +192.19% | +18.52% | -20.00% | -50.73% | +102.22% |
| Net Income | -15,200 | -14,220 | 200,640 | -7,600 | 4,640 |
| Net Income Growth | -6.89% | -107.09% | +2,740.00% | -263.79% | -74.19% |
Kyntra Bio Inc (KYNB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Kyntra Bio is a biopharmaceutical company focused on development of novel therapies in oncology and rare disease. Kyntra Bio, formerly known as FibroGen Inc., is based in SAN FRANCISCO.
Fiscal Year End Date: 12/31